Portola, part 1: the new drug application for betrixaban

Two readers emailed in to point out that I misinterpreted the meaning of the net clinical benefit figure. As much as I hate being wrong, I hate misleading people even more  – so I’ve pulled the piece until I get a chance to take another look at the data.

A word of thanks for the readers who wrote in with their disagreements.

 

2 thoughts on “Portola, part 1: the new drug application for betrixaban”

  1. I am stunned by your inability to understand trial results, although since you seem to be anonymous I assume you hope to create a selloff before the FDA decision is rendered.

Leave a Reply to Peter Miniatus Cancel reply

Your email address will not be published. Required fields are marked *